Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2026)

Design Therapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $215.1 million in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $215.1 million, down 3.48% year-over-year; the trailing twelve-month figure through Jun 2026 was $883.5 million (down 9.29% YoY), and the FY2025 annual result was $226.2 million, down 10.27% from the prior year.
• Liabilities and Shareholders Equity fell to $215.1 million in Q2 2026, from $230.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $378.8 million in Q1 2022 and troughed at $211.8 million in Q3 2025.
• A 5-year average of $281.9 million and a median of $274.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2025, when Liabilities and Shareholders Equity declined 19.06%; it then dropped 2.96% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $341.1 million in 2022, then declined by 15.09% to $289.6 million in 2023, then declined by 12.96% to $252.1 million in 2024, then dropped by 10.27% to $226.2 million in 2025, then fell by 4.9% to $215.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $215.1 million in Q2 2026, $230.4 million in Q1 2026, and $226.2 million in Q4 2025.